Key result
DEB yields similar 1-year MACCE rates to DES in acute MI from in-stent restenosis.
Why the study?
Few reports exist about drug-eluting balloon use in acute myocardial infarction with in-stent restenosis, motivating evaluation of its efficacy.
Cohort (n=117)
No
Absolute Event Rate: 34% vs 35.7%
p-value: p=0.688
DEB yields comparable MACE to DES in AMI-ISR; extends stable ISR data but leaves open need for RCTs before practice change.
Background Good results of drug-eluting balloon (DEB) use are achieved in in-stent restenosis (ISR) lesions, small vessel disease, long lesions, and bifurcations. However, few reports exist about DEB use in acute myocardial infarction (AMI) with ISR. This study’s aim was to evaluate the efficacy of DEB for AMI with ISR. Methods Between November 2011 and December 2015, 117 consecutive patients experienced AMI including ST-segment elevation MI, and non-ST-segment elevation MI due to ISR, and received percutaneous coronary intervention (PCI). We divided our patients into two groups: (1) PCI with further DEB, and (2) PCI with further drug-eluting stent (DES). Clinical outcomes such as target lesion revascularization, target vessel revascularization, recurrent MI, stroke, cardiovascular mortality, and all-cause mortality were analyzed. Results The patients’ average age was 68.37 ± 11.41 years; 69.2% were male. A total of 75 patients were enrolled in the DEB group, and 42 patients were enrolled in the DES group. The baseline characteristics between the two groups were the same without statistical differences except for gender. Peak levels of cardiac biomarker, pre- and post-PCI cardiac function were similar between two groups. The major adverse cardiac cerebral events rate (34.0% vs. 35.7%; p = 0.688) and cardiovascular mortality rate (11.7% vs. 12.8%; p = 1.000) were similar in both groups. Conclusions DEB is a reasonable strategy for AMI with ISR. Compared with DES, DEB is an alternative strategy which yielded acceptable short-term outcomes and similar 1-year clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Fang et al. (2018) conducted a cohort in Acute myocardial infarction due to in-stent restenosis (n=117). Drug-eluting balloon (DEB) vs. Drug-eluting stent (DES) was evaluated on Major adverse cardiac cerebral events (MACCE) during the 1-year follow-up period (p=0.688). Drug-eluting balloons yielded a similar 1-year rate of major adverse cardiac cerebral events compared to drug-eluting stents (34.0% vs. 35.7%) in patients with acute myocardial infarction due to in-stent restenosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: